Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056555610> ?p ?o ?g. }
- W2056555610 endingPage "172" @default.
- W2056555610 startingPage "167" @default.
- W2056555610 abstract "Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.BackgroundIgA nephropathy (IgAN) is the most common glomerulonephritis with various histologic and clinical phenotypes. The mechanisms underlying the pathogenesis of IgAN remained unclear. But now altered O-glycosylation of serum IgA1 observed in these patients was considered to be a key contributory factor. The aim of the current study is to investigate whether aberrantly glycosylated IgA1 was associated with pathologic phenotypes of IgAN.MethodsSera from 107 patients with IgAN recently diagnosed were collected. Fifty patients were with mild mesangial proliferative IgAN, the others were with focal proliferative and sclerosing IgAN. Sera from 22 normal blood donors were used as normal controls. Biotinylated lectins were used in enzyme-linked immunosorbent assay (ELISA) to examine different glycans on IgA1 molecules. The α2,6 sialic acid was detected by elderberry bark lectin (SNA), the exposure of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) were detected by arachis hypogaea [peanut agglutinin (PNA)] and vilsa villosa lectin (VVL), respectively. The serum IgA1 glycans levels corrected by serum IgA1 concentrations were compared between patients and controls.ResultsReduced terminal α2,6 sialic acid (1.16 ± 0.21 vs. 0.98 ± 0.31) (P = 0.008) and galactosylation (0.30 ± 0.29 vs. 0.16 ± 0.19) (P = 0.029) increased exposure of (GalNAc) (0.00 vs. 0.03) (P = 0.024) were demonstrated in serum IgA1 from patients with IgAN as compared with those in controls. More important, the exposures of 2,6 sialic acid and Gal were significantly decreased, especially in patients with focal proliferative and sclerosing IgAN compared with that in patients with mild mesangial proliferative IgAN (0.91 ± 0.34 vs. 1.05 ± 0.25) (P = 0.014) (0.108 ± 0.137 vs. 0.221 ± 0.219) (P = 0.018). However, no significant difference was found between patients with mild mesangial proliferative IgAN and normal controls (P > 0.05). The exposure of GalNAc of serum IgA1 from patients with focal proliferative and sclerosing IgAN was significantly higher than that of controls (P = 0.017), but had no statistical difference with that of patients with mild mesangial proliferative IgAN.ConclusionThe desialylation and degalactosylation of IgA1 in sera of patients with IgAN were closely associated with pathologic phenotypes. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. IgA nephropathy (IgAN) is the most common glomerulonephritis with various histologic and clinical phenotypes. The mechanisms underlying the pathogenesis of IgAN remained unclear. But now altered O-glycosylation of serum IgA1 observed in these patients was considered to be a key contributory factor. The aim of the current study is to investigate whether aberrantly glycosylated IgA1 was associated with pathologic phenotypes of IgAN. Sera from 107 patients with IgAN recently diagnosed were collected. Fifty patients were with mild mesangial proliferative IgAN, the others were with focal proliferative and sclerosing IgAN. Sera from 22 normal blood donors were used as normal controls. Biotinylated lectins were used in enzyme-linked immunosorbent assay (ELISA) to examine different glycans on IgA1 molecules. The α2,6 sialic acid was detected by elderberry bark lectin (SNA), the exposure of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) were detected by arachis hypogaea [peanut agglutinin (PNA)] and vilsa villosa lectin (VVL), respectively. The serum IgA1 glycans levels corrected by serum IgA1 concentrations were compared between patients and controls. Reduced terminal α2,6 sialic acid (1.16 ± 0.21 vs. 0.98 ± 0.31) (P = 0.008) and galactosylation (0.30 ± 0.29 vs. 0.16 ± 0.19) (P = 0.029) increased exposure of (GalNAc) (0.00 vs. 0.03) (P = 0.024) were demonstrated in serum IgA1 from patients with IgAN as compared with those in controls. More important, the exposures of 2,6 sialic acid and Gal were significantly decreased, especially in patients with focal proliferative and sclerosing IgAN compared with that in patients with mild mesangial proliferative IgAN (0.91 ± 0.34 vs. 1.05 ± 0.25) (P = 0.014) (0.108 ± 0.137 vs. 0.221 ± 0.219) (P = 0.018). However, no significant difference was found between patients with mild mesangial proliferative IgAN and normal controls (P > 0.05). The exposure of GalNAc of serum IgA1 from patients with focal proliferative and sclerosing IgAN was significantly higher than that of controls (P = 0.017), but had no statistical difference with that of patients with mild mesangial proliferative IgAN. The desialylation and degalactosylation of IgA1 in sera of patients with IgAN were closely associated with pathologic phenotypes." @default.
- W2056555610 created "2016-06-24" @default.
- W2056555610 creator A5008236609 @default.
- W2056555610 creator A5084817248 @default.
- W2056555610 date "2005-07-01" @default.
- W2056555610 modified "2023-09-23" @default.
- W2056555610 title "Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy" @default.
- W2056555610 cites W1553723618 @default.
- W2056555610 cites W1840824980 @default.
- W2056555610 cites W1959238477 @default.
- W2056555610 cites W1965019591 @default.
- W2056555610 cites W1965998306 @default.
- W2056555610 cites W1975362922 @default.
- W2056555610 cites W1982085852 @default.
- W2056555610 cites W1982950890 @default.
- W2056555610 cites W1992322707 @default.
- W2056555610 cites W1993857686 @default.
- W2056555610 cites W2026103095 @default.
- W2056555610 cites W2030254556 @default.
- W2056555610 cites W2031807034 @default.
- W2056555610 cites W2044279814 @default.
- W2056555610 cites W2055398180 @default.
- W2056555610 cites W2055507506 @default.
- W2056555610 cites W2055585414 @default.
- W2056555610 cites W2070286548 @default.
- W2056555610 cites W2079113954 @default.
- W2056555610 cites W2079344868 @default.
- W2056555610 cites W2081377478 @default.
- W2056555610 cites W2085114555 @default.
- W2056555610 cites W2099377647 @default.
- W2056555610 cites W2100063226 @default.
- W2056555610 cites W2108843703 @default.
- W2056555610 cites W2141986806 @default.
- W2056555610 cites W2143014918 @default.
- W2056555610 cites W2147558603 @default.
- W2056555610 cites W2153592027 @default.
- W2056555610 cites W2158523132 @default.
- W2056555610 cites W2168715586 @default.
- W2056555610 cites W2171232600 @default.
- W2056555610 doi "https://doi.org/10.1111/j.1523-1755.2005.00390.x" @default.
- W2056555610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15954905" @default.
- W2056555610 hasPublicationYear "2005" @default.
- W2056555610 type Work @default.
- W2056555610 sameAs 2056555610 @default.
- W2056555610 citedByCount "85" @default.
- W2056555610 countsByYear W20565556102012 @default.
- W2056555610 countsByYear W20565556102013 @default.
- W2056555610 countsByYear W20565556102014 @default.
- W2056555610 countsByYear W20565556102015 @default.
- W2056555610 countsByYear W20565556102016 @default.
- W2056555610 countsByYear W20565556102017 @default.
- W2056555610 countsByYear W20565556102018 @default.
- W2056555610 countsByYear W20565556102019 @default.
- W2056555610 countsByYear W20565556102020 @default.
- W2056555610 countsByYear W20565556102021 @default.
- W2056555610 countsByYear W20565556102022 @default.
- W2056555610 countsByYear W20565556102023 @default.
- W2056555610 crossrefType "journal-article" @default.
- W2056555610 hasAuthorship W2056555610A5008236609 @default.
- W2056555610 hasAuthorship W2056555610A5084817248 @default.
- W2056555610 hasBestOaLocation W20565556101 @default.
- W2056555610 hasConcept C104317684 @default.
- W2056555610 hasConcept C126322002 @default.
- W2056555610 hasConcept C127716648 @default.
- W2056555610 hasConcept C134018914 @default.
- W2056555610 hasConcept C203014093 @default.
- W2056555610 hasConcept C2777313579 @default.
- W2056555610 hasConcept C2780091579 @default.
- W2056555610 hasConcept C2780115458 @default.
- W2056555610 hasConcept C2780368995 @default.
- W2056555610 hasConcept C2780758401 @default.
- W2056555610 hasConcept C2780942790 @default.
- W2056555610 hasConcept C2781184683 @default.
- W2056555610 hasConcept C55493867 @default.
- W2056555610 hasConcept C555293320 @default.
- W2056555610 hasConcept C71924100 @default.
- W2056555610 hasConcept C86803240 @default.
- W2056555610 hasConceptScore W2056555610C104317684 @default.
- W2056555610 hasConceptScore W2056555610C126322002 @default.
- W2056555610 hasConceptScore W2056555610C127716648 @default.
- W2056555610 hasConceptScore W2056555610C134018914 @default.
- W2056555610 hasConceptScore W2056555610C203014093 @default.
- W2056555610 hasConceptScore W2056555610C2777313579 @default.
- W2056555610 hasConceptScore W2056555610C2780091579 @default.
- W2056555610 hasConceptScore W2056555610C2780115458 @default.
- W2056555610 hasConceptScore W2056555610C2780368995 @default.
- W2056555610 hasConceptScore W2056555610C2780758401 @default.
- W2056555610 hasConceptScore W2056555610C2780942790 @default.
- W2056555610 hasConceptScore W2056555610C2781184683 @default.
- W2056555610 hasConceptScore W2056555610C55493867 @default.
- W2056555610 hasConceptScore W2056555610C555293320 @default.
- W2056555610 hasConceptScore W2056555610C71924100 @default.
- W2056555610 hasConceptScore W2056555610C86803240 @default.
- W2056555610 hasIssue "1" @default.
- W2056555610 hasLocation W20565556101 @default.
- W2056555610 hasLocation W20565556102 @default.
- W2056555610 hasOpenAccess W2056555610 @default.
- W2056555610 hasPrimaryLocation W20565556101 @default.